

Bora establishes leadership position in Taiwan's CDMO sector with new acquisition

10 May 2022 | News

Bora Pharmaceuticals acquires Eden Biologics CDMO assets



Taiwan-based contract development and manufacturing organization (CDMO) Bora Pharmaceuticals has recently announced the establishment of Bora Biologics Co., Ltd., a CDMO platform for biologics.

Besides Bora, investors into the new entity include Taishin Healthcare Limited Partnership and Tanvex BioPharma founder Dr Allen Chao.

Bora has also announced that they will initially invest \$50 million and up to \$100 million in the acquisition of Eden Biologics' CDMO assets in Taiwan as part of its 5-year growth plan.

With Bora's strengths as a CDMO for small molecules and biological macromolecules, the company has established a leadership position in Taiwan with its comprehensive CDMO customer services and competitive market share.

Bora indicated that the strategic acquisition of Eden Biologics CDMO assets, located in Hsinchu Biomedical Science Park, Taiwan, will help Bora Group rapidly build a presence in the biological macromolecules and cell and gene therapy markets, and position the organization to expand its service offering to their clients supporting new and innovative drug development.

With the acquisition of the facility, Bora will have biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, along with the establishment of quality control and inspection specifications, as well as cell bank generation.